Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Gossamer Bio, Inc. GOSS
$1.25
-$0.1 (-7.78%)
На 18:01, 12 мая 2023
+200.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
132190073.00000000
-
week52high
15.20
-
week52low
0.91
-
Revenue
0
-
P/E TTM
0
-
Beta
1.20073100
-
EPS
-2.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:01
Описание компании
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Overweight | Overweight | 18 авг 2022 г. |
| Raymond James | Outperform | Outperform | 10 авг 2022 г. |
| Raymond James | Outperform | Outperform | 14 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| Raymond James | Outperform | Outperform | 26 апр 2022 г. |
| JP Morgan | Neutral | 21 сент 2022 г. | |
| Wedbush | Outperform | 19 сент 2022 г. | |
| Goldman Sachs | Buy | 20 окт 2022 г. | |
| Raymond James | Outperform | Outperform | 17 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 08 дек 2022 г. |
| UBS | Buy | Buy | 07 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 дек 2022 г. |
| SMBC Nikko | Neutral | Outperform | 07 дек 2022 г. |
| Raymond James | Outperform | Outperform | 07 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Carter Laura | A | 157500 | 157500 | 07 дек 2022 г. |
| Peterson Caryn | A | 157500 | 157500 | 07 дек 2022 г. |
| Aranda Richard | A | 157500 | 157500 | 07 дек 2022 г. |
| Christian Waage | A | 157500 | 157500 | 07 дек 2022 г. |
| Hasnain Faheem | A | 544500 | 544500 | 07 дек 2022 г. |
| Giraudo Bryan | A | 211500 | 211500 | 07 дек 2022 г. |
| Carter Laura | D | 82292 | 4876 | 24 окт 2022 г. |
| Peterson Caryn | D | 61415 | 4757 | 24 окт 2022 г. |
| Aranda Richard | D | 205430 | 4757 | 24 окт 2022 г. |
| Christian Waage | A | 13888 | 6934 | 15 июл 2022 г. |
Новостная лента
Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib
Seeking Alpha
02 апр 2023 г. в 04:12
Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations, and is moving forward with a revised Phase 3 trial.
10 Top Penny Stocks To Watch With High Short Interest This Week
PennyStocks
31 янв 2023 г. в 14:30
More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore
Seeking Alpha
30 янв 2023 г. в 04:48
Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positive surprises can lead to a meaningful stock rally.
4 Penny Stocks To Watch With High Short Interest In January 2023
PennyStocks
27 янв 2023 г. в 12:14
Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
04 янв 2023 г. в 13:32
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).